Chemo cocktail takes on rare bladder cancers
NCT ID NCT00082706
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a combination of four chemotherapy drugs (5-FU, leucovorin, gemcitabine, and cisplatin) in 46 people with advanced or inoperable adenocarcinoma of the bladder, urethra, or urachus. The goal was to see how many patients' tumors shrank or disappeared. Researchers also monitored severe side effects to determine if the combination is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of four chemotherapy drugs: 5-FU, leucovorin, gemcitabine, and cisplatin
- What this could lead to
- If successful, this drug combination could offer a new treatment option for people with advanced bladder or urachal cancers that cannot be removed by surgery.
- What could go wrong
- This is a small, early-phase trial (46 participants) with no control group, so results may not apply broadly. The chemotherapy combination has significant side effects, including dose-limiting toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE URACHAL REMNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Can One-Piece tumour removal improve bladder cancer outcomes?